Presenilin-1 Expression Cassettes With Low-CpG Codon Optimization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapies for neurodegenerative disorders, such as Alzheimer's disease, face challenges in efficiently delivering therapeutic genes like presenilin-1 due to suboptimal expression levels and high CpG dinucleotide content, which can lead to immune response issues.
Innovation Solution
Development of codon-optimized polynucleotides and expression cassettes encoding presenilin-1 with reduced CpG dinucleotides and optimized codons, combined with AAV vectors and neuron-specific promoters, to enhance gene expression and delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If native presenilin-1 coding sequence is used for gene therapy, then the gene maintains natural sequence integrity, but expression levels are suboptimal and CpG dinucleotide content is high causing immune responses
Solution Approach 1:
The patent applies codon optimization by changing synonymous codons in the presenilin-1 coding sequence to match human codon usage preferences, thereby improving translation efficiency and expression levels without altering the amino acid sequence. Additionally, CpG dinucleotides are reduced or eliminated through targeted codon substitutions, which prevents activation of immune responses while maintaining the therapeutic protein's function.
Solution Approach 2:
The patent replaces the native genomic DNA sequence with a synthetically optimized cDNA sequence that encodes the same protein but with improved expression characteristics. This substitution allows for enhanced translational efficiency and reduced immunogenicity while preserving the therapeutic effect of the presenilin-1 protein.
2Productivity
If codon optimization is applied to improve expression levels, then therapeutic efficacy increases, but sequence fidelity to native gene may be compromised
Solution Approach 1:
The patent optimizes codon usage by substituting synonymous codons to match human preferences, which improves translation efficiency and protein expression levels. The optimization process carefully maintains the amino acid sequence identity while adjusting only the nucleotide sequence to enhance expression without compromising the protein's functional integrity.
Data Source
AI summary
The disclosure relates to nucleic acid expression cassettes for the treatment of neurodegenerative disorders. Methods of treating neurodegenerative disorders such as Alzheimer's disease, frontotemporal dementia, frontotemporal lobar degeneration, Pick's disease, Lewy body dementia, memory loss, cognitive impairment, and mild cognitive impairment are also provided.